**Supplementary Fig. 5. Forest plot of sustained virologic response with SOF/VEL, SOF/LDV, and SOF/DCV regimens to treat patients with any genotype and decompensated cirrhosis.** The SVR rates were 91.0% (95% CI: 87.7–93.9) with SOF/VEL, n=882; 86.3% (95% CI: 84.6–87.8), n=2805 with SOF/LDV; and 82.4% (95% CI: 78.2–86.2) with SOF/DCV, n=1615; p=0.0023. SOF, sofosbuvir; LDV, ledipasvir; VEL, velpatasvir; DCV, daclatasvir; RBV, ribavirin; SVR, sustained virologic response.

